Interferons (alpha), Peginterferon, Ropeginterferon
RISK OF SERIOUS DISORDERS
Risk of Serious Disorders
- Alpha interferons, including peginterferon alfa-2a, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders.
- Patients should be monitored closely with periodic clinical and laboratory evaluations.
- Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions.
- In many, but not all cases, these disorders resolve after stopping therapy
MONITORING RECOMMENDATIONS RELATED TO BLACK BOX DATA
- Close monitoring of depressive symptomatology and periodic neuropsychiatric evaluation during therapy.
- Persistent severe or worsening signs or symptoms may necessitate discontinuation of therapy
Patient Counseling Information
Medication Guides
Patient Medication Guide - Itron A (Interferon Alfa-2b)
Patient Medication Guide - BESREMI (Ropeginterferon Alfa-2b-Nift)
Package Inserts
Additional Information
Interferon Alfa-2b (Intron A) products have been discontinued.
Updated December 2021